免疫吸附治疗THSD7A抗体阳性膜性肾病
本文报道2例THSD7A抗体阳性膜性肾病患者,采用免疫吸附清除血浆中的THSD7A抗体后,蛋白尿迅速减少。结果支持THSD7A抗体在肾病综合征发病中的致病作用,提示免疫吸附可能是该类患者的有效治疗手段。
要点
- 免疫吸附可快速降低THSD7A抗体阳性膜性肾病患者的蛋白尿。
- THSD7A抗体在膜性肾病肾病综合征中具致病作用。
- 免疫吸附或可作为THSD7A抗体阳性膜性肾病的治疗工具。
核心结论
- 免疫吸附清除THSD7A抗体可使THSD7A抗体阳性膜性肾病患者蛋白尿迅速减少。
- 研究结果支持并强化THSD7A抗体在肾病综合征发生中的致病作用。
- 2例病例提示免疫吸附可能是THSD7A抗体阳性膜性肾病的有用治疗工具。
研究设计与样本
- 病例报告,共2例THSD7A抗体阳性膜性肾病患者。
- 干预为使用免疫吸附从血浆中清除THSD7A抗体。
主要发现
- 2例THSD7A抗体阳性膜性肾病患者经免疫吸附后蛋白尿迅速减少。
临床怎么用
- 对THSD7A抗体阳性膜性肾病患者,可考虑免疫吸附作为清除抗体、减少蛋白尿的治疗选择。
局限性
- 仅基于2例病例报告,证据级别有限,结论需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibodies against THSD7A (thrombospondin type 1 domain-containing protein 7A) have been proposed to play a causal role in the development of nephrotic syndrome in patients with THSD7A antibody-positive membranous nephropathy. We hypothesized that removal of these antibodies from plasma could lead to a rapid reduction in proteinuria. Using immunoadsorption to reduce THSD7A antibodies led to a rapid reduction in proteinuria in 2 patients with THSD7A antibody-positive membranous nephropathy. Moreover, our findings support and strengthen the pathogenic role of the antibodies in the development of nephrotic syndrome in patients with THSD7A antibody-positive membranous nephropathy. Taken together, these 2 cases suggest that immunoadsorption could be a useful tool in the treatment of patients with THSD7A antibody-positive membranous nephropathy.
引用
- Weinmann-Menke J, Holtz S, Sollinger D, et al. Treatment of Membranous Nephropathy in Patients With THSD7A Antibodies Using Immunoadsorption. Am J Kidney Dis. 2019. PMID: 31451329. doi:10.1053/j.ajkd.2019.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。